fluoxetine and sumatriptan

Both fluoxetine and sumatriptan increase serotonergic activity. Fluoxetine inhibits serotonin reuptake via presynaptic serotonin transporter inhibition, while sumatriptan is a selective agonist at serotonin 5-HT1B/1D receptors. Their combined action can lead to excessive serotonin stimulation in the central and peripheral nervous system, particularly in the brainstem and spinal cord.

The clinical consequence is serotonin syndrome, a potentially life-threatening condition. Symptoms may include cognitive changes such as confusion or agitation, autonomic instability (hypertension, hyperthermia, diaphoresis, tachycardia), and neuromuscular abnormalities (hyperreflexia, myoclonus, tremor, incoordination). The interaction is most likely with higher doses of either agent, and onset can be rapid.

Prescribers should be cautious, especially if the patient requires both drugs. Consider alternative treatments where possible. If co-prescription is necessary, closely monitor the patient for emerging symptoms of serotonin syndrome, particularly in the first days of therapy or after dose changes. Advise the patient to seek medical attention if they experience symptoms such as confusion, sweating, tremors, or muscle twitching. Consider dose reduction of sumatriptan or fluoxetine, or using a different triptan or antiemetic.

The interaction is well established based on pharmacological plausibility and multiple case reports of serotonin syndrome with the combination of SSRIs and triptans. Regulatory warnings have been issued, although some reviews suggest the absolute risk is low. The potential severity justifies caution, but the incidence is not precisely quantified.